{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:36:09Z","timestamp":1794332169032,"version":"4.9.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Iberdomide is a BCS III CELMoD\u2122 agent currently under development for treatment of multiple myeloma. Five formulations were used during clinical development, starting with active ingredient in gelatin capsule (AIC), followed by subsequent formulations in gelatin (F1), HPMC capsules (F2 and F3), and finally the intended commercial form (ICF). A food effect study with the Phase I AIC formulation showed no food effect and two relative bioavailability studies bridging from AIC to formulation F1 and F2 showed similar systemic exposure. Modeling and simulation, based on <jats:italic>in vitro<\/jats:italic> dissolution, was used to bridge gaps in clinical data to demonstrate lack of a food effect across all formulations including ICF. First, a previously developed population pharmacokinetic (PK) model showed that formulation was not a covariate on iberdomide PK. Then a physiologically-based pharmacokinetic model (PBPK) informed by <jats:italic>in vitro<\/jats:italic> biorelevant dissolution was used to mechanistically describe iberdomide absorption. While minor differences between formulations were noted in their <jats:italic>in vitro<\/jats:italic> dissolution, PBPK modeling showed lack of a food effect across all five formulations. Sensitivity analysis using the PBPK model demonstrated that iberdomide permeability and total amount of drug released from formulation are the most sensitive parameters in defining the systemic exposure of iberdomide, in agreement with iberdomide\u2019s BCS III classification where drug release from drug product, and not solubility, is the rate-limiting step of dissolution. Based on the totality of evidence, which included clinical and <jats:italic>in vitro<\/jats:italic> data supplemented by modeling and simulation, no food effect is expected with the ICF.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01071-4","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:04:06Z","timestamp":1745939046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of Iberdomide"],"prefix":"10.1208","volume":"27","author":[{"given":"Caroline","family":"Sychterz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gaohua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-9418","authenticated-orcid":false,"given":"Yiming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"11","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol. 2022;9(11):e822\u201332.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1071_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/cpdd.869","volume":"10","author":"Y Ye","year":"2021","unstructured":"Ye Y, Gaudy A, Schafer P, Thomas M, Weiss D, Chen N, et al. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety\/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator. Clin Pharmacol Drug Dev. 2021;10(5):471\u201385.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1071_CR3","first-page":"9","volume":"15","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, et al. A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects. Clin Pharmacol. 2023;15:9\u201319.","journal-title":"Clin Pharmacol"},{"issue":"2","key":"1071_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00228-020-03004-w","volume":"77","author":"A Gaudy","year":"2021","unstructured":"Gaudy A, Atsriku C, Ye Y, MacGorman K, Liu L, Xue Y, et al. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects. Eur J Clin Pharmacol. 2021;77(2):223\u201331.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1071_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13318-024-00886-4","volume":"49","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wang X, Liu L, Silva J, Thomas M, Li Y. A Phase I, Open-Label, Mass Balance Study of [(14)C]-Iberdomide in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2024;49(3):355\u201365.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"1071_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1021\/acsmedchemlett.1c00475","volume":"12","author":"NR Kong","year":"2021","unstructured":"Kong NR, Liu H, Che J, Jones LH. Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition. ACS Med Chem Lett. 2021;12(11):1861\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"1071_CR7","doi-asserted-by":"publisher","unstructured":"Lonial S, Quach H, Dimopoulos MA, Rodr\u00edguez-Otero P, Berdeja JG, Richardson PG, et al. EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):TPS8069-TPS. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8069.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069"},{"key":"1071_CR8","unstructured":"Bristol Myers Squibb. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma. Identifier NCT05827016. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05827016."},{"key":"1071_CR9","unstructured":"Assessing the Effects of Food on Drugs in INDs and NDAs - Clinical Pharmacology Considerations. In: US Department of Health and Human Services FaDAF, editor. 2022."},{"issue":"2","key":"1071_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11095-022-03373-0","volume":"40","author":"D Wu","year":"2023","unstructured":"Wu D, Li M. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development. Pharm Res. 2023;40(2):321\u201336.","journal-title":"Pharm Res"},{"issue":"1","key":"1071_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bcp.15498","volume":"89","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Xue Y, Chen L, Masin M, Maciag P, Peluso T, et al. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma. Br J Clin Pharmacol. 2023;89(1):316\u201329.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.xphs.2025.01.015","volume":"114","author":"P Chen","year":"2025","unstructured":"Chen P, Lin H, Xue Y, Thomas M, Wang A, Li Y, et al. A Population Pharmacokinetic Analysis to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Iberdomide. J Pharm Sci. 2025;114(2):1315\u201325.","journal-title":"J Pharm Sci"},{"key":"1071_CR13","unstructured":"Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances. In: US Department of Health and Human Services FaDAF, editor. 2018."},{"issue":"8","key":"1071_CR14","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"R Madabushi","year":"2022","unstructured":"Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making. Pharm Res. 2022;39(8):1669\u201380.","journal-title":"Pharm Res"},{"issue":"6","key":"1071_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1208\/s12248-020-00508-2","volume":"22","author":"AE Riedmaier","year":"2020","unstructured":"Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, et al. Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. AAPS J. 2020;22(6):123.","journal-title":"AAPS J"},{"issue":"2","key":"1071_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.xphs.2023.11.030","volume":"113","author":"S Kollipara","year":"2024","unstructured":"Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini A, Ahmed T. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives. J Pharm Sci. 2024;113(2):345\u201358.","journal-title":"J Pharm Sci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01071-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:51:44Z","timestamp":1751637104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01071-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01071-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS, PC, AS, HL, LC, YL, LG and YC are employees of and own stock in Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"85"}}